European ScreeningPort offers assay development services for primary and selectivity screens and hit validation studies. For each project, an individual critical path is defined which matches the biology and chemistry requirements of the target to the most appropriate assay technology platform available.
Our capabilities range from the adaptation of existing assays to robust, high throughput compatible formats of pharmacological relevance to the creation and generation of reagents e.g. recombinant proteins and cell lines for new targets, substrates, probes and inhibitors. Building on our experience and that of our partners, with a track record of over 250 assays developed, we can provide you with assays for all major target classes including:
- Ion channels
- Kinases
- Proteases
- Lipases
- GPCRs
- Protein/protein interactions
- Receptor/ligand interaction
If appropriate, we can access a panel of fully validated generic assay formats with well defined pharmacological properties to progress your project rapidly and increase the potential for success.
For High Throughput Screening scale studies all major fluorometric readouts and biologically relevant assay formats are represented in addition to high content applications:
- Bulk fluorescence
- Fluorescence polarisation
- Fluorescence lifetime
- TR-FRET
- FRET
- Luminescence
- Absorbance
- Calcium mobilization (FLIPR)
- ELISA
- AlphaScreen
- Cellular imaging
- Fluorescent Microscopy
- Enzyme Assays
- Reporter Assays
- Viability Assays
- Protein Translocation
In addition we can offer the full range of proprietary FCS+ readout technologies which offer unmatched data quality and the opportunity to work at the 1µl scale, if reagent supply is an issue. For compound profiling, and medium scale screens, we have access to radiometric and qPCR, LC/MS based assay technologies, as well as biophysical formats (protein-NMR, X-ray crystallography) for detailed mechanistic studies.
